Current Problems in Cancer
Volume 34, Issue 1 , Pages 97-107 , January 2010

Systemic Treatments for Merkel Cell Carcinoma

  • Ragini Kudchadkar, MD

      Affiliations

    • Moffitt Cancer Center and Department of Oncologic Sciences, University of South Florida, Tampa, Florida
    • ,
  • Ronald Deconti, MD

      Affiliations

    • Department of Oncologic Sciences, University of South Florida, Tampa, Florida

References 

  1. Eng TY, Boersma MG, Fuller CD, Cavanaugh SX, Valenzuela F, Herman TS. Treatment of Merkel cell carcinoma. Am J Clin Oncol. 2004;27:510–515
  2. Medina-Franco H, Urist MM, Fiveash J, Heslin MJ, Bland KI, Beenken SW. Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol. 2001;8:204–208
  3. Eng TY, Boersam MG, Fuller CD, Goytia V, Jones WE, Joyner M, et al. A comprehensive review of the treatment of Merkel cell carcinoma. Am J Clin Oncol. 2007;30:624–636
  4. McAfee WJ, Morris CG, Mendenhall CM, Werning JW, Mendenhall NP, Mendenhall WM. Merkel cell carcinoma. Cancer. 2005;104:1761–1764
  5. King MM, Osswald MB. Adjuvant chemotherapy for Merkel cell carcinoma. Am J Clin Oncol. 2005;28:634
  6. Kokoska ER, Kokoska MS, Collins BT, Stapleton DR, Wade TP. Early aggressive treatment for Merkel cell carcinoma improves outcome. Am J Surg. 1997;174:688–693
  7. Poulsen M, Rischin D, Walpole E, Harvey J, Mackintosh J, Ainslie J, et al. High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group study—TROG. J Clin Oncol. 2003;96:4371–4376
  8. Poulsen M, Walpole E, Harvey J, Dickie G, O'Brien P, Keller J, et al. Weekly carboplatin reduces toxicity during synchronous chemoradiotherapy for Merkel cell carcinoma of skin. Int J Radiat Oncol Biol Phys. 2008;72:1070–1074
  9. Poon D, Yap SP, Mancer K, Quek ST, Soh LT. Induction chemotherapy followed by radiotherapy in Merkel cell carcinoma. Lancet Oncol. 2004;5:509–510
  10. Pectasides D, Pectasides M, Psyrri A, Koumarianou A, Xiros N, Pectasides E, et al. Cisplatin-based chemotherapy for Merkel cell carcinoma of the skin. Cancer Invest. 2006;24:780–785
  11. Davis MP, Miller EM, Rau RC, Johnson OE, Naille RA, Crnkovich MJ. The use of vp16 and cisplatin in the treatment of Merkel cell carcinoma. J Dermatol Surg Oncol. 1990;16:276–278
  12. Fenig E, Lurie H, Sulkes A. The use of cyclophosphamide, methotrexate and 5-flourouracil in the treatment of Merkel cell carcinoma. Am J Clin Oncol. 1993;16:54–57
  13. Fenig E, Brenner B, Katz A, Rakovsky E, Hana MB, Sulkes A. The role of radiation therapy and chemotherapy in the treatment of Merkel cell carcinoma. Cancer. 1997;80:881–885
  14. Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol. 2005;23:2300–2309
  15. Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol. 2003;49:832–841
  16. Hodgson NC. Merkel cell carcinoma: changing incidence trends. J Surg Oncol. 2005;89:1–4
  17. Goldberg SR, Neifeld JP, Frable WJ. Prognostic value of tumor thickness in patients with Merkel cell carcinoma. J Surg Oncol. 2007;95:618–622
  18. Sandel HD4th, Day T, Richardson MS, Scarlett M, Gutman KA. Merkel cell carcinoma: dose tumor size or depth of invasion correlate with recurrence, metastasis, or patient survival?. Laryngoscope. 2006;116:791–795
  19. Poulsen MG, Rischin D, Porter I, Walpole E, Harvey J, Hamilton C, et al. Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin?. Int J Radiat Oncol Biol Phys. 2006;64:114–119
  20. Koljonen V, Böhling T, Granhroth G, Tukiainen E. Merkel cell carcinoma: a clinicopathological study of 34 patients. Eur J Surg Oncol. 2003;29:607–610
  21. Clark JR, Veness MJ, Gilbert R, O'Brien CJ, Gullane PJ. Merkel cell carcinoma of the head and neck: is adjuvant radiotherapy necessary?. Head Neck. 2007;29:249–257
  22. Gupta AS, Heinzman S, Levine EA. Successful treatment of in-transit metastases from Merkel's cell carcinoma with isolated hyperthermic limb perfusion. South Med J. 1998;91:289–292
  23. Olieman AF, Liénard D, Eggermont AM, Kroon BB, Lejeune FJ, Hoekstra HJ, et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities. Arch Surg. 1999;134:303–307
  24. Ponte P, Moniz JV, Farricha V, Weinholtz JB. Merkel cell carcinoma: an unusual indication for isolated limb perfusion. Dermatol Online J. 2008;14:6
  25. Grandpeix C, Bonvalot S, Petrow P, Fraitag S, Gounod N, Avril MF. Continued complete remission of Merkel cell carcinoma with in-transit metastasis after treatment with isolated limb perfusion regional chemotherapy. Ann Dermatol Venereol. 2006;133(8-9 Pt. 1):700–703
  26. Duprat JP, Domingues AL, Coelho EG, Leal RM, Nishinari K, Neves RI. Long-term response of isolated limb perfusion with hyperthermia and chemotherapy for Merkel cell carcinoma. Eur J Surg Oncol. 2009;35:568–572
  27. Voog E, Biron P, Martin JP, Blay JY. Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer. 1999;85:2589–2595
  28. Tai PT, Yu E, Winquist E, Hammond A, Stitt L, Tonita J, et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol. 2000;18:2493–2499
  29. Boyle F, Pendlebury S, Bell D. Further insights into the natural history and management of primary cutaneous neuroendocrine (Merkel Cell) carcinoma. Int J Radiat Oncol Biol Phys. 1995;31:315–323
  30. Wynne CJ, Kearsely JH. Merkel cell tumor: a chemosensitive cancer. Cancer. 1988;62:28–31
  31. Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a minnie pearl cancer research network study. J Clin Oncol. 2006;24:3548–3554
  32. Bajetta E, Zilemob N, Di Bartolomeo M, Di Leo A, Pilotti S, Bochicchio AM, et al. Treatment of metastatic carcinoid and other neuroendocrine tumors with recombinant interferon-alpha-2b: a study by the Italian Trials in Medical Oncology Group. Cancer. 1993;72:3099–3105
  33. Durand JM, Weiller C, Richard MA, Portal I, Mongin M. Treatment of Merkel cell tumor with interferon-alpha-2b. Br J Dermatol. 1991;124:509
  34. Ito Y, Kawamura K, Miura T, Ueda K, Onodera H, Takahashi H, et al. Merkel cell carcinoma: a successful treatment with tumor necrosis factor. Arch Dermatol. 1989;125:1093–1095
  35. Hata Y, Matsuka K, Ito O, Matsuda H, Furuichi H, Konstantinos A, et al. Two cases of Merkel cell carcinoma cured by intratumor injection of natural human tumor necrosis factor. Plast Reconstr Surg. 1997;99:547–553
  36. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319:1096–1100
  37. Rockville Merkel Cell Carcinoma Group. Merkel cell carcinoma: recent progress and current priorities on etiology, pathogenesis, and clinical management. J Clin Oncol. 2009;27:4021–4026
  38. Feinmesser M, Halpern M, Fenig E, Tsabari C, Hodak E, Sulkes J, et al. Expression of the apoptosis-related oncogenes Bcl-2, Bax, and p53 in Merkel cell carcinoma: can they predict treatment response and clinical outcome?. Hum Pathol. 1999;30:1367–1372
  39. Kennedy MM, Blessing K, King G, Kerr KM. Expression of Bcl-2 and p53 in Merkel cell carcinoma (An immunohistochemical study). Am J Dermatopathol. 1996;18:273–277
  40. Shah MH, Varker KA, Collamore M, Zwiebel JA, Coit D, Kelsen D, et al. G3139 (Genasense) in patients with advanced merkel cell carcinoma. Am J Clin Oncol. 2009;32:174–179
  41. Lassacher A, Heitzer E, Kerl H, Wolf P. p14ARF hypermethylation is common but INK4a-ARF locus or p53 mutations are rate in Merkel cell carcinoma. J Invest Dermatol. 2008;128:1788–1796

PII: S0147-0272(10)00016-4

doi: 10.1016/j.currproblcancer.2010.01.004

Current Problems in Cancer
Volume 34, Issue 1 , Pages 97-107 , January 2010

Article Tools